R&D / Pipeline
ella®/ellaOne®
ella®/ellaOne® is an innovative next-generation emergency contraceptive pill based on the new chemical entity ulipristal acetate. ella®/ellaOne® prevents pregnancy from occurring when taken within 120 hours (5 days) after unprotected intercourse or contraceptive failure. This is the first ever drug to have been specifically designed and developed for use as an emergency contraceptive.
In May 2009, ellaOne® (ulipristal acetate), has been granted marketing authorization by the European Commission. ellaOne® is marketed throughout the entire European Union, directly by HRA Pharma in the UK, Germany, Italy, Spain and France and via partner companies elsewhere.
On August 13, 2010, the US Food and Drug Administration (FDA) granted approval for ella® (ulipristal acetate) as a prescription-only emergency contraceptive indicated for use within 120 hours (five days) of unprotected intercourse or a known or suspected contraceptive failure. ella® is marketed in the US by HRA Pharma's partner Watson Pharmaceuticals, Inc.
The company plans to file for marketing approvals in countries worldwide under the trademarks ellaOne® and ella®, and continues to research pharmaceutical developments in the field of reproductive health that are better adapted to women's lifestyles.